u/hana_lehtinen

Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.

What are you planning to watch for, and over what period?

reproducibility beats resolution if you only get one of them

Right, and the diabetes programmes report glycaemic endpoints. Quoting an obesity trial result here is answering a different question.

FFMI is a ratio and it moves when either term moves

emil_okwuosa is right that protein becomes a logistics problem when appetite drops.

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

SSA sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.

a shoulder is not an impurity until you can resolve it

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

LC-MS for identity, UV for relative quantity

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.

Have you taken this to whoever manages your diabetes?

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Have the lifts held, dropped, or moved around?

What did system suitability look like on that sequence?

Is that a weight number from a different programme?

Do you have the mass, or only the UV trace?

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

Cosigning that postprandial excursions improve first and the fasting number is the laggard.

sensor accuracy varies and the first day of a sensor is the worst

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

Interval stretching lowers the trough concentration while keeping the dose; dose reduction lowers the level while keeping the rhythm. They are different interventions with different subjective profiles.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

dose for glycaemic control is not the same conversation as dose for weight

Do you have a written baseline from before you started changing anything?

Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Agreed. A1c is an integrated average over roughly three months and treating it as a current reading causes a lot of unnecessary alarm.

decide what you are watching for before you stop

Agreed — and the exposure lag means the first fortnight tells you almost nothing.

Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.

Mass spectrometry answers identity.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

Fasting or postprandial?

Do you have a written baseline from before you started changing anything?

What does time in range look like, not just the average?